First Quarter 2008 - Issues in Hematology - ION Solutions

More documents

Recommendations

Info

nurse’s forumOUTPATIENT MANAGEMENT OF TUMORLYSIS SYNDROME IN PATIENTS WITHDIFFUSE LARGE B-CELL LYMPHOMA:CONSIDERATIONS FOR THEONCOLOGY NURSEby: Tamika M. Turner, M.S.N., N.P.-C., O.C.N.oncologistics volume 7, issue 1 - spring 2008 46Approximately 80-90% of chemotherapy is given inthe outpatient setting. 1 Oncology nurses who work inoutpatient chemotherapy infusion clinics are the keyplayers in fi rst recognizing adverse side effects fromchemotherapy. These nurses spend time with patientsfrom the initiation of chemotherapy to the completion ofeach infusion. Oncology nurses must be knowledgeableregarding the possible adverse reactions of eachchemotherapy medication infused to appropriatelycare for patients in this setting.The purpose of this article is to review tumor lysissyndrome as it relates to patients with non-Hodgkinlymphoma (NHL). This article will review one type ofNHL commonly treated in the outpatient infusion clinic,commonly used chemotherapy regimens to treat this typeof lymphoma, adverse reactions to these chemotherapymedications to include tumor lysis syndrome, and oncologynursing considerations.NHL is the fi fth most common cancer in men and womenin the United States: approximately 64,000 people inthe United States were diagnosed with non-Hodgkinlymphoma in 2007. 2 Lymphomas occur when lymphocytesundergo a malignant change. This change causes thecell to multiply out of control and crowd out healthy cells,thus causing tumors in the lymphatic system. The mostcommon places for lymphomas to start are in the lymphnodes or in organs like the stomach or intestines. Theseorgans have collections of lymphatic tissue that make themprone for lymphomas to originate. 2The oncology nurse may be asked what it is that increasesa patient’s risk for lymphoma. The incidence of NHL hasalmost doubled over the last century, and there are anumber of possible factors that may increase the risk forNHL. Immunosuppression is one of those risk factors.Patients with HIV have approximately 50 to 100 times theincidence of NHL than those without HIV. The Epstein-Barr virus has been found to increase the risk for Burkettlymphoma and Helicobacter pylori has been found toincrease the risk for MALT or gastric lymphoma. Farmershave also been found to have an increased risk for NHL.It is thought that this is from the pesticides and herbicidesused to maintain farms and/or crops. 2Diffuse large B-cell lymphoma is the most aggressive formof NHL and the most common form in the Western world.These lymphomas are aggressive but can be curable.Diffuse large B-cell lymphomas have large B lymphocytesmaking up the tumors, and there is usually extranodaland widespread involvement. Patients may present witha variety of symptoms, such as enlarged lymph nodes inthe neck, axillary area, or groin. Occasional symptoms willoccur in other areas of the body, such as bone, lung, orgastrointestinal tract. These patients may experience bonepain, cough, or gastrointestinal distress. Other symptomsmay include unexplained weight loss,
oncologistics nurse’s forumoncologistics 47
Page 2 and 3: C O M I N G S O O NfromCEPHALON ONC
Page 4 and 5: © 2007 Bristol-Myers Squibb Compan
Page 6 and 7: industry insightHOSPIRA’S INCREAS
Page 8 and 9: industry insightWhat core competenc
Page 10 and 11: industry insightWhat differentiates
Page 12 and 13: XELODAEfficacy that makes a differe
Page 14 and 15: Brief summary of prescribing inform
Page 16 and 17: oncologistics volume 7, issue 1 - s
Page 20 and 21: IV IRON SUPPORTTHROUGHOUT CHEMOTHER
Page 22 and 23: established, and the test dose has
Page 24 and 25: eimbursement watchoncologistics vol
Page 26 and 27: eimbursement watch14236132158151241
Page 28 and 29: eimbursement watchon a coverage top
Page 30 and 31: drug updateTHESE STUDIESDEMONSTRATE
Page 32 and 33: drug updateoncologistics volume 7,
Page 34 and 35: POWER ANDPERFORMANCEVIDAZA hits MDS
Page 36 and 37: drug updateBased on recent findings
Page 38 and 39: drug updatehad been met. Median OS
Page 40 and 41: drug update(PDGF-ß), FLT-3, RET, a
Page 42 and 43: FURTHER PROGRESS IN THE TREATMENT O
Page 48 and 49: nurse’s forumoncologistics volume
Page 50 and 51: oncologistics eye on ionEYE on IONG
Page 52 and 53: Note for printer: NOVARTIS 2PG INSE
Page 55 and 56: “ ION provides me with a better v

First Quarter 2008 - Issues in Hematology - ION Solutions

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?